Breakthroughs in Alzheimer's Treatment: Weekly Injections
Alzheimer’s Treatment Briefing
Coverage period: December 2–8, 2025 (U.S.)
Below are the most important, genuinely new developments from the past seven days that affect how we treat — or soon might treat — Alzheimer’s disease.
Top stories (ranked)
- Lecanemab by injection looks as effective as IV — and may cause fewer infusion reactions
- Overview
- New results presented December 3 at the CTAD meeting show that starting lecanemab with weekly under‑the‑skin injections produced drug levels equivalent to the standard IV infusions every two weeks. Safety and amyloid‑clearing effects were similar in modeling analyses, and systemic infusion reactions were lower with injections in the reported cohorts. (media-us.eisai.com)
- Why this matters
- If regulators clear “start‑by‑injection,” clinics could move treatment out of infusion chairs, reduce staffing bottlenecks, and make access easier for patients and caregivers — without sacrificing effectiveness. (media-us.eisai.com)
- How much time could lecanemab buy? New modeling suggests larger gains with early, continued use
- Overview
- A CTAD analysis estimated “time saved” (slower worsening) when people start lecanemab early and stay on it. In those with low amyloid at the start, the model suggested up to about 8 years of delay in reaching moderate‑stage disease versus natural decline; for the overall group, smaller but still meaningful delays were estimated. This is modeling, not proof from a head‑to‑head 10‑year trial. Presented December 3. (prnewswire.com)
- Why this matters
- For care planning, this supports starting sooner rather than later and continuing treatment once risks are managed. It also helps families and programs weigh the effort of MRIs and monitoring against potential long‑term benefit. (prnewswire.com)
- Semaglutide Alzheimer’s trials detailed at CTAD: clinically negative despite biomarker hints
- Overview
- On December 4, fuller readouts confirmed two large Phase 3 trials of oral semaglutide did not slow memory or function in early Alzheimer’s, despite some small changes in lab measures. Investigators called the results clearly negative for symptomatic treatment. (reuters.com)
- Why this matters
- For people with symptoms today, GLP‑1 drugs used for diabetes/weight loss should not be expected to help cognition. Research interest is likely to shift to prevention settings (years before symptoms), while current symptomatic care remains centered on anti‑amyloid and emerging anti‑tau approaches. (reuters.com)
- Blood test p‑tau217 strengthens its case for spotting Alzheimer’s years earlier
- Overview
- A new meta‑analysis published online in JAMA Neurology this week pooled 18 studies (7,834 people without cognitive symptoms) and found that a simple blood measure, p‑tau217, was highly accurate at identifying who already has Alzheimer‑type brain changes (AUC ~0.87). (jamanetwork.com)
- Why this matters
- Earlier, easier detection can funnel the right patients to disease‑slowing treatments and trials — and reduce the need for costly PET scans or spinal taps in many cases. Clinics can use blood tests to triage who needs confirmatory testing and who is likely eligible for treatment. (jamanetwork.com)
- Tau therapy momentum: Merck’s anti‑tau antibody advances with FDA Fast Track and first‑in‑human data
- Overview
- December 1 (within our 7‑day window): Merck reported Phase 1 safety/pharmacology results for MK‑2214, which targets a disease‑related form of tau, and noted FDA Fast Track status. A Phase 2 study in early Alzheimer’s is underway. (merck.com)
- Why this matters
- Today’s approved drugs target amyloid. A safe, effective tau‑directed medicine could be paired with amyloid‑clearing drugs to deepen or prolong benefit — a key next step for the field. Fast Track can speed development. (merck.com)
What this means for care right now
- Access could get easier soon: Injection‑based lecanemab initiation appears comparable to IV and may trigger fewer infusion‑type reactions, which would reduce clinic burden if approved. Keep MRI safety monitoring protocols in place. (media-us.eisai.com)
- Start early when appropriate: Modeling supports earlier and continued treatment for greater long‑term benefit; use this to guide expectations and care planning while acknowledging these are projections, not decade‑long trial outcomes. (prnewswire.com)
- Set expectations on non‑amyloid drugs: GLP‑1 medicines like semaglutide are not helping once symptoms are present; do not divert resources from proven options for symptomatic early Alzheimer’s. (reuters.com)
- Use blood tests to triage: p‑tau217 can help identify who likely has Alzheimer’s brain changes and should proceed to confirmatory testing or treatment evaluation, streamlining patient flow. (jamanetwork.com)
Dates to note (for clarity)
- Dec 1–4, 2025: CTAD meeting where lecanemab injection data, time‑benefit modeling, semaglutide results, and MK‑2214 updates were presented. (media-us.eisai.com)
If you’d like, I can push a quick mid‑week update if regulators issue any follow‑ups on lecanemab injection initiation from the CTAD data.